Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,227.47
    -2,857.82 (-3.32%)
     

  • CMC Crypto 200

    1,259.18
    -98.83 (-7.28%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Is BioDelivery Sciences (BDSI) a Great Growth Stock?

Zacks Equity Research
Updated

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is BioDelivery Sciences International, Inc. BDSI. This firm, which is in the Biomedical and Genetics space, saw EPS growth of 15.3% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 45.7%. Furthermore, the long-term growth rate is currently an impressive 25%, suggesting pretty good prospects for the long haul.

BioDelivery Sciences International, Inc. Price and Consensus

BioDelivery Sciences International, Inc. Price and Consensus | BioDelivery Sciences International, Inc. Quote

ADVERTISEMENT

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 3.8%. Thanks to this rise in earnings estimates, BDSI has a Zacks Rank #2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider BDSI. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for BDSI as well.

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?

Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research